Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF6001 DPI Add-on to Triple Therapy in COPD with Chronic Bronchitis
2023-510174-13-00Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Annual rate of moderate and severe exacerbations over 52 weeks. Started Aug 2024; status: completed.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2023-510174-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510174-13-00.